BRIEF—Marinomed receives EU nod for common cold therapy

Vienna-based Marinomed Biotech has received EU-wide approval for a new common cold treatment.

The company describes the therapy as a nasal spray that alleviates nasal congestion without use of a pharmaceutical ingredient, while simultaneously combatting the viral infection of the airways using the respiratory therapy Carragelose (carrageenan).

"With this certification, our new product is marketable throughout the EU," explained Eva Prieschl-Grassauer, founder and board member at Marinomed. "This year, we will launch the product in Austria – under the brand name Coldamaris akut – and in Switzerland."

As a result, Marinomed is set to further expand its product range, which currently comprises of five different products including nasal, throat sprays and lozenges, available in more than 30 countries.